Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

Active — Not RecruitingPhase 2

NCT07274761

Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.

To assess the efficacy and safety of sunvozertinib as neoadjuvant therapy in patients with stage II-IIIB non-small cell lung cancer (NSCLC) harboring epidermal…

China24 participantsStarted 2024-10-17

Treatment: Sunvozertinib